CA2475277A1 - Procede pour produire des proteines de recombinaison dans des micro-organismes - Google Patents
Procede pour produire des proteines de recombinaison dans des micro-organismes Download PDFInfo
- Publication number
- CA2475277A1 CA2475277A1 CA002475277A CA2475277A CA2475277A1 CA 2475277 A1 CA2475277 A1 CA 2475277A1 CA 002475277 A CA002475277 A CA 002475277A CA 2475277 A CA2475277 A CA 2475277A CA 2475277 A1 CA2475277 A1 CA 2475277A1
- Authority
- CA
- Canada
- Prior art keywords
- plasminogen
- glu
- lys
- seq
- nucleic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
Abstract
La présente invention concerne un procédé pour produire un plasminogène de recombinaison fonctionnel dans des micro-organismes et un procédé pour identifier des activateurs de plasminogène. La séquence d'acides nucléiques codant la partie fonctionnelle du plasminogène est fusionnée avec une molécule d'acide nucléique qui code au moins un peptide signal. La molécule d'acide nucléique codant le plasminogène et la molécule d'acide nucléique codant le peptide signal sont combinées avec des codons d'interface de protéases qui assurent le détachement du peptide signal. Le plasminogène de recombinaison et la plasmine correspondante sont utilisés pour traiter des plaies qui guérissent lentement ou qui ne guérissent pas, par application de l'enzyme se trouvant dans une formulation adéquate.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02002716 | 2002-02-06 | ||
EP02002716.5 | 2002-02-06 | ||
US35780902P | 2002-02-21 | 2002-02-21 | |
US60/357,809 | 2002-02-21 | ||
PCT/DE2003/000341 WO2003066842A2 (fr) | 2002-02-06 | 2003-02-06 | Procede pour produire des proteines de recombinaison dans des micro-organismes |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2475277A1 true CA2475277A1 (fr) | 2003-08-14 |
Family
ID=36743321
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002475277A Abandoned CA2475277A1 (fr) | 2002-02-06 | 2003-02-06 | Procede pour produire des proteines de recombinaison dans des micro-organismes |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1472346A2 (fr) |
JP (1) | JP2005525798A (fr) |
CN (1) | CN1768138A (fr) |
AU (1) | AU2003210137A1 (fr) |
CA (1) | CA2475277A1 (fr) |
MX (1) | MXPA04007585A (fr) |
WO (1) | WO2003066842A2 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11207387B2 (en) | 2016-12-15 | 2021-12-28 | Talengen International Limited | Method and drug for preventing and treating obesity |
US11338022B2 (en) | 2015-12-18 | 2022-05-24 | Talengen International Limited | Method for preventing and treating angiocardiopathy |
US11478535B2 (en) | 2016-12-15 | 2022-10-25 | Talengen International Limited | Method for preventing and treating fatty liver |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2453496T3 (es) | 2006-08-28 | 2014-04-08 | Omnio Healer Ab | Diana farmacológica novedosa de prevención y tratamiento de enfermedad periodontal, mejora de la cicatrización de heridas periodontales y promoción de la salud oral |
CN101573134B (zh) | 2006-08-28 | 2013-03-06 | 李季男 | 抗感染候选药物 |
KR20120050442A (ko) | 2009-07-10 | 2012-05-18 | 쓰롬보제닉스 엔.브이. | 플라스미노겐 및 플라스민의 변이체 |
CA2778526A1 (fr) * | 2009-10-30 | 2011-05-05 | Merck Sharp & Dohme Corp. | Procede de fabrication de proteines therapeutiques dans la lignee cellulaire pichia pastoris, depourvue d'activite dipeptidyl aminopeptidase |
JP6085568B2 (ja) | 2011-01-05 | 2017-02-22 | スロンボジェニックス・ナムローゼ・フェンノートシャップThromboGenics NV | プラスミノーゲンおよびプラスミンの変異体 |
AU2012296884B2 (en) | 2011-08-12 | 2015-02-05 | Thrombogenics N.V. | Plasminogen and plasmin variants |
CN106890323A (zh) * | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防和治疗肝组织损伤及其相关病症的方法 |
US10709771B2 (en) | 2015-12-18 | 2020-07-14 | Talengen International Limited | Method for preventing or treating diabetic retinopathy |
TWI653981B (zh) | 2015-12-18 | 2019-03-21 | 深圳瑞健生命科學硏究院有限公司 | Use of plasminogen for the preparation of a medicament for preventing or treating a condition associated with diabetic nerve injury |
CN106890319A (zh) * | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种预防或治疗糖尿病性视网膜病变的方法 |
CA3008495A1 (fr) | 2015-12-18 | 2017-06-22 | Talengen International Limited | Methode destinee a prevenir et traiter une erosion cervicale |
CA3008475A1 (fr) * | 2015-12-18 | 2017-06-22 | Talengen International Limited | Procede pour eviter et traiter les lesions tissulaires hepatiques et les troubles lies a celles-ci |
CN106890320A (zh) * | 2015-12-18 | 2017-06-27 | 深圳瑞健生命科学研究院有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
CN108463236A (zh) | 2015-12-18 | 2018-08-28 | 泰伦基国际有限公司 | 一种预防或治疗放射性和化学性损伤的方法 |
CN108472342B (zh) * | 2015-12-18 | 2022-11-15 | 泰伦基国际有限公司 | 一种用于预防或治疗急性及慢性血栓的方法 |
CA3008686C (fr) | 2015-12-18 | 2023-03-14 | Talengen International Limited | Procede pour empecher et traiter une nephropathie diabetique |
CN108210904A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 治疗动脉粥样硬化及其并发症的药物及其用途 |
CA3047175A1 (fr) | 2016-12-15 | 2018-06-21 | Talengen International Limited | Procede pour attenuer une maladie cardiaque |
JP7242057B2 (ja) * | 2016-12-15 | 2023-03-20 | タレンゲン インターナショナル リミテッド | 薬物性腎損傷を予防及び治療するための方法 |
CN110191718A (zh) * | 2016-12-15 | 2019-08-30 | 泰伦基国际有限公司 | 一种预防和治疗组织器官纤维化的方法 |
TWI644682B (zh) | 2016-12-15 | 2018-12-21 | 深圳瑞健生命科學硏究院有限公司 | 一種纖溶酶原在製備促進胰島細胞損傷修復的藥物上的用途 |
CN108210915A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 改善心脏病变的药物及其用途 |
CN108210911A (zh) * | 2016-12-15 | 2018-06-29 | 深圳瑞健生命科学研究院有限公司 | 一种促进胰岛素分泌的方法 |
CN111344004A (zh) | 2017-06-19 | 2020-06-26 | 泰伦基国际有限公司 | 一种调控glp-1/glp-1r 的方法和药物 |
CN109971736B (zh) * | 2017-12-27 | 2021-07-23 | 中科院大连化物所盘锦产业技术研究院有限公司 | 与草莓软化相关的氨基己糖苷酶及编码基因、制备与应用 |
CN110358780A (zh) * | 2018-04-10 | 2019-10-22 | 东莞泛亚太生物科技有限公司 | 一种编码β-甘露聚糖酶的基因,以及含该基因的重组质粒和重组菌及其构建方法 |
CN109456989B (zh) * | 2018-10-31 | 2022-03-29 | 陕西慧康生物科技有限责任公司 | 一种提高毕赤酵母分泌表达的载体的构建方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190756A (en) * | 1989-12-01 | 1993-03-02 | Genentech, Inc. | Methods and materials for expression of human plasminogen variant |
GB9222758D0 (en) * | 1992-10-29 | 1992-12-09 | British Bio Technology | Proteins and nucleic acids |
WO2002050290A1 (fr) * | 2000-12-21 | 2002-06-27 | Thromb-X Nv | Vecteur d'expression de levure et production d'une proteine recombinee d'une cellule de levure |
-
2003
- 2003-02-06 CA CA002475277A patent/CA2475277A1/fr not_active Abandoned
- 2003-02-06 EP EP20030737248 patent/EP1472346A2/fr not_active Withdrawn
- 2003-02-06 JP JP2003566193A patent/JP2005525798A/ja active Pending
- 2003-02-06 AU AU2003210137A patent/AU2003210137A1/en not_active Abandoned
- 2003-02-06 CN CNA038033267A patent/CN1768138A/zh active Pending
- 2003-02-06 MX MXPA04007585A patent/MXPA04007585A/es unknown
- 2003-02-06 WO PCT/DE2003/000341 patent/WO2003066842A2/fr active Application Filing
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11338022B2 (en) | 2015-12-18 | 2022-05-24 | Talengen International Limited | Method for preventing and treating angiocardiopathy |
US11207387B2 (en) | 2016-12-15 | 2021-12-28 | Talengen International Limited | Method and drug for preventing and treating obesity |
US11478535B2 (en) | 2016-12-15 | 2022-10-25 | Talengen International Limited | Method for preventing and treating fatty liver |
Also Published As
Publication number | Publication date |
---|---|
JP2005525798A (ja) | 2005-09-02 |
CN1768138A (zh) | 2006-05-03 |
WO2003066842A2 (fr) | 2003-08-14 |
WO2003066842A3 (fr) | 2004-06-10 |
AU2003210137A1 (en) | 2003-09-02 |
AU2003210137A8 (en) | 2003-09-02 |
MXPA04007585A (es) | 2005-09-20 |
EP1472346A2 (fr) | 2004-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2475277A1 (fr) | Procede pour produire des proteines de recombinaison dans des micro-organismes | |
JP2851423B2 (ja) | 活性化可能なフィブリン溶解および抗血栓症タンパク質 | |
CA2125783C (fr) | Methodes de production de thrombine | |
US20050124036A1 (en) | Method for producing recombinant proteins in micro-organisms | |
EP0225286B1 (fr) | Agent fibrinolytique | |
US20050175581A1 (en) | Biological entities and the pharmaceutical and diagnostic use thereof | |
NZ203869A (en) | Functional human urokinase: preparation by recombinant dna techniques and/or by cleaving bioinactive precursor | |
CA2272244A1 (fr) | Collagenase recombinee type i provenant du clostridium histolyticum, et son utilisation pour l'isolation des cellules et des agglomerations cellulaires | |
WO1992006211A1 (fr) | Procede pour produire un peptide ou une proteine | |
JPH07147984A (ja) | ポリクリングルプラスミノーゲン活性化因子をコードする遺伝子およびそれを含有するベクター | |
JPH07507448A (ja) | 向上した治療特性を有する組織プラスミノーゲン活性化因子グリコシル化変異体 | |
HU201115B (en) | Process for producing fibrinolitic materials with yeast | |
WO2006067198A2 (fr) | Nouvelles entites biologiques et utilisation ciblee de celles-ci | |
US5338546A (en) | Tissue plasminogen activator variants with decreased clearance | |
KR100983878B1 (ko) | 유전자 재조합 기술에 의한 인간 트롬빈 제조 방법 | |
US5747291A (en) | Bifunctional urokinase variants with improved fibrinolytic characteristics and thrombin inhibiting effect | |
EP2202306B1 (fr) | Facteur de coagulation sanguine x recombinant sans glycosylation et son procédé de préparation | |
DK175369B1 (da) | Anvendelse af tPA-varianter til fremstilling af et terapeutisk præparat til behandling af vaskulæresygdomme | |
JP3696617B2 (ja) | フィブリン特異性が改善されたt‐PA置換変異体 | |
JP3126381B2 (ja) | 減少されたクリアランスを有する組織プラスミノーゲンアクチベーター変異体 | |
CA2360585A1 (fr) | Protease | |
NZ246432A (en) | Fibrin-specific t-pa with a point mutation at position 276, vector cell cultures | |
JP2005278550A (ja) | 2本鎖組織プラスミノーゲンアクチベーターの製造法 | |
HU210541A9 (hu) | Zimogén- vagy fibrin-specifikus tulajdonságú, a 296-299 aminosav-tartományban helyettesített szöveti plazminogén aktivátor, ezt kódoló DNS-molekulák, vektorok és gazdasejtek | |
NL8902651A (nl) | Farmaceutisch preparaat met endoproteolytische activiteit; werkwijze voor endoproteolytische processing van eiwitten. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |